Blog
Complete inventive entity required to avoid “by another” prior art under pre-AIA § 102(e)
The US Court of Appeals for the Federal Circuit affirmed the Patent Trial & Appeal Board’s decision finding claims directed to cladribine regimens for treating multiple sclerosis unpatentable as obvious….
By: McDermott Will & Schulte